Denali Therapeutics Inc. (DNLI)
$18.40-2.90%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.9B
- Beta
- 1.02
- P/E (TTM)
- -6.48
- Short % float
- 10.72%
- Days to cover
- 7.6
- SI change
- -9.8%
- 1W
- -4.56%
- 1M
- -13.29%
- vs SPY 1W
- -4.43%
- vs SPY 1M
- -15.80%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 16$142.44-4.41%
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28-2.95%
- PRAXSELLPraxis Precision Medicines, Inc.$7.2BCRISISQ 11$259.86-3.20%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 7$28.14-2.29%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-3.30%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 24$30.65-3.85%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on DNLI?
- LOPJLB’s latest quantitative signal on Denali Therapeutics Inc. (DNLI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DNLI in?
- Denali Therapeutics Inc. (DNLI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Denali Therapeutics Inc. (DNLI) do?
- Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecul…